AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16729760 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard treatment + bioactive substances in formula CognoBlend (2 capsules twice a day for 5 weeks)
Number of subjects: 66
Study 16729760 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment
Number of subjects: 66
Study 15314590 — intervention group
Group type: EXPERIMENTAL
Intervention: Subtenons lidocaine injection (1 ml of 2% lidocaine)
Number of subjects: 111
Study 15314590 — intervention group
Group type: COMPARATOR
Intervention: Control group (no subtenons lidocaine injection)
Number of subjects: 111
Study 11230794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) spectroscopy to determine HDL particle size and subclasses
Number of subjects: 918
Study 11230794 — intervention group
Group type: EXPERIMENTAL
Intervention: Nuclear magnetic resonance (NMR) spectroscopy to determine HDL subclasses
Number of subjects: 918
Study 9294492 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment at a daily subcutaneous dose of 0.2 or 0.3 IU/kg for 2 years
Number of subjects: 21
Study 9294492 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone (GH) treatment
Number of subjects: 21
Study 8322989 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg of diamorphine added to 4 ml of 0.5% bupivacaine
Number of subjects: 60
Study 8322989 — intervention group
Group type: COMPARATOR
Intervention: 4 ml of 0.5% bupivacaine alone
Number of subjects: 60
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Case history (CH) combined with skin tests (ST)
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: RAST (allergen-specific serum IgE)
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin tests (ST) combined with either RAST or basophil histamine release (HR)
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Basophil histamine release (HR) as a single analysis
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Various combinations of tests
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Altering the concentration of allergen
Number of subjects: 26
Study 2422973 — intervention group
Group type: EXPERIMENTAL
Intervention: Bronchial provocation tests (BPT)
Number of subjects: 26
Study 29652275 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketofol infusion (ketamine: propofol, 1mg: 3 mg in 20 ml syringe)
Number of subjects: 50
Study 29652275 — intervention group
Group type: COMPARATOR
Intervention: Dexmedetomidine infusion (200 μg in 20 ml normal saline)
Number of subjects: 50
Study 27443361 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-anchored intermaxillary traction (BAIMT)
Number of subjects: 38
Study 27443361 — intervention group
Group type: COMPARATOR
Intervention: Removable mandibular retractor (RMR)
Number of subjects: 38
Study 24418653 — intervention group
Group type: EXPERIMENTAL
Intervention: CB bibliotherapy
Number of subjects: 378
Study 24418653 — intervention group
Group type: EXPERIMENTAL
Intervention: CB group
Number of subjects: 378
Study 24418653 — intervention group
Group type: COMPARATOR
Intervention: Control condition (educational brochure)
Number of subjects: 378
Study 22687642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for two months (PIO 15)
Number of subjects: 0
Study 22687642 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg/day for one month followed by 30 mg/day for an additional one month (PIO 30)
Number of subjects: 0
Study 20138037 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PES
Number of subjects: 50
Study 20138037 — intervention group
Group type: COMPARATOR
Intervention: Sham PES (Control)
Number of subjects: 50
Study 18477013 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation during pregnancy and lactation
Number of subjects: 171
Study 18477013 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 18477013 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation
Number of subjects: 171
Study 18477013 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic supplementation in allergic mothers
Number of subjects: 171
Study 15625255 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient Controlled Inhalational Induction (PCI)
Number of subjects: 124
Study 15625255 — intervention group
Group type: COMPARATOR
Intervention: Vital Capacity Inhalational Induction (VCI)
Number of subjects: 124
Study 12649050 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet history interview
Number of subjects: 56
Study 12649050 — intervention group
Group type: COMPARATOR
Intervention: Food record
Number of subjects: 56
Study 10961590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide CIR 15 mg
Number of subjects: 258
Study 10961590 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide CIR 9 mg
Number of subjects: 258
Study 10961590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 9200284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride 10 mg, four times daily for 4 weeks
Number of subjects: 70
Study 9200284 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 9200284 — intervention group
Group type: COMPARATOR
Intervention: Cisapride and Placebo
Number of subjects: 70
Study 9200284 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisapride
Number of subjects: 70
Study 1487921 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 40 st/min
Number of subjects: 12
Study 1487921 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 60 st/min
Number of subjects: 12
Study 1487921 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairobic stepping (SS) at 80 st/min
Number of subjects: 12
Study 1487921 — intervention group
Group type: COMPARATOR
Intervention: Bench stepping (BS) at 20 st/min
Number of subjects: 12
Study 1487921 — intervention group
Group type: COMPARATOR
Intervention: Bench stepping (BS) at 30 st/min
Number of subjects: 12
Study 1487921 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairobic MET (SM) at two lowest SS rates
Number of subjects: 12
Study 1487921 — intervention group
Group type: EXPERIMENTAL
Intervention: Stairobic MET (SM) at highest SS rate
Number of subjects: 12
Study 1487921 — intervention group
Group type: COMPARATOR
Intervention: Physiologic cost of BS
Number of subjects: 12
Study 3103572 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75 mg/kg of tissue plasminogen activator (rt‐PA)
Number of subjects: 37
Study 3103572 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 31658051 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous omega-3 poly-unsaturated fatty acids (n-3 PUFAs)
Number of subjects: 44
Study 31658051 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 44
Study 28940323 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenwal Amicus
Number of subjects: 57
Study 28940323 — intervention group
Group type: COMPARATOR
Intervention: Terumo BCT Spectra Optia
Number of subjects: 57
Study 27843165 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal mortality rate
Number of subjects: 149570
Study 27843165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality within 24 hours of birth
Number of subjects: 149570
Study 27843165 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality within the first 6 hours
Number of subjects: 149570
Study 24104513 — intervention group
Group type: EXPERIMENTAL
Intervention: Training programme for joint attention and imitation
Number of subjects: 36
Study 24104513 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 36
Study 22542530 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin (10 mg/day)
Number of subjects: 50
Study 22542530 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg/day) / Ezetimibe (10 mg/day)
Number of subjects: 50
Study 20087195 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-nightly dosing (didanosine plus lamivudine with efavirenz)
Number of subjects: 87
Study 20087195 — intervention group
Group type: COMPARATOR
Intervention: Twice-daily dosing (combivir with efavirenz)
Number of subjects: 87
Study 20087195 — intervention group
Group type: EXPERIMENTAL
Intervention: Once-nightly dosing
Number of subjects: 87
Study 20087195 — intervention group
Group type: EXPERIMENTAL
Intervention: High initial concerns about HAART
Number of subjects: 87
Study 18833174 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial dynamic magnetic therapy (along with basic therapy)
Number of subjects: 54
Study 18833174 — intervention group
Group type: COMPARATOR
Intervention: Basic therapy
Number of subjects: 54
Study 15921965 — intervention group
Group type: EXPERIMENTAL
Intervention: Niflumic acid quantitation using HPLC method with UV detection (288 nm)
Number of subjects: 0
Study 15921965 — intervention group
Group type: EXPERIMENTAL
Intervention: Niflumic acid levels in plasma samples
Number of subjects: 0
Study 14695440 — intervention group
Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum strains supplementation
Number of subjects: 0
Study 9640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 20 vpm
Number of subjects: 19
Study 9640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 1 vpm
Number of subjects: 19
Study 9640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 40 vpm
Number of subjects: 19
Study 9640146 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide at 10 vpm
Number of subjects: 19
Study 7660402 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated levels of lipoprotein(a) [Lp(a)]
Number of subjects: 885
Study 7660402 — intervention group
Group type: COMPARATOR
Intervention: Hormone replacement therapy in women
Number of subjects: 885
Study 7660402 — intervention group
Group type: EXPERIMENTAL
Intervention: Lp(a) as a predictor of carotid atherosclerosis
Number of subjects: 885
Study 7660402 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen and antithrombin III
Number of subjects: 885
Study 2855516 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and smoking intervention
Number of subjects: 1232
Study 29778980 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AFO provision (at inclusion)
Number of subjects: 26
Study 29778980 — intervention group
Group type: COMPARATOR
Intervention: Delayed AFO provision (eight weeks later)
Number of subjects: 26
Study 29778980 — intervention group
Group type: EXPERIMENTAL
Intervention: Early AFO provision
Number of subjects: 26
Study 29778980 — intervention group
Group type: COMPARATOR
Intervention: Delayed AFO provision
Number of subjects: 26
Study 26538105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 3 months starting at 12 months post-operation
Number of subjects: 12
Study 26538105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFMT) starting at 15 months post-operation
Number of subjects: 12
Study 26538105 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle training (PFMT) for 3 months
Number of subjects: 12
Study 26538105 — intervention group
Group type: COMPARATOR
Intervention: Control group (no PFMT)
Number of subjects: 12
Study 25700806 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) 400 mcg and umeclidinium (UMEC) 500 mcg administered in combination (FF/UMEC 100/125 mcg)
Number of subjects: 18
Study 25700806 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone furoate (FF) 100 mcg
Number of subjects: 18
Study 25700806 — intervention group
Group type: COMPARATOR
Intervention: Umeclidinium (UMEC) 125 mcg
Number of subjects: 18
Study 22950541 — intervention group
Group type: EXPERIMENTAL
Intervention: Prescribed fluid equal to sweat loss (1.65 +/- 0.17 litres)
Number of subjects: 13
Study 22950541 — intervention group
Group type: EXPERIMENTAL
Intervention: Ad libitum fluid (0.85 +/- 0.19 litres)
Number of subjects: 13
Study 22950541 — intervention group
Group type: EXPERIMENTAL
Intervention: No fluid
Number of subjects: 13
Study 21885255 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal transcranial direct current stimulation (tDCS) at 1 mA for 20 min
Number of subjects: 5
Study 21885255 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 5
Study 19542781 — intervention group
Group type: EXPERIMENTAL
Intervention: 200-m fast-walk test
Number of subjects: 30
Study 19542781 — intervention group
Group type: COMPARATOR
Intervention: 6-min walk test
Number of subjects: 30
Study 19542781 — intervention group
Group type: COMPARATOR
Intervention: Cardiopulmonary exercise test
Number of subjects: 30
Study 16415377 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 mg atorvastatin per day
Number of subjects: 471
Study 16415377 — intervention group
Group type: COMPARATOR
Intervention: 10 mg atorvastatin per day
Number of subjects: 471
Study 15228801 — intervention group
Group type: EXPERIMENTAL
Intervention: Mental practice (MP) for mobility tasks
Number of subjects: 12
Study 11331680 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal lead burden (measured in blood and bone)
Number of subjects: 329
Study 11331680 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breastfeeding
Number of subjects: 329
Study 11331680 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal patella lead levels
Number of subjects: 329
Study 9204729 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention by Umbanda healers on biomedical prevention of AIDS
Number of subjects: 126
Study 9204729 — intervention group
Group type: COMPARATOR
Intervention: Untrained controls
Number of subjects: 126
Study 8357774 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril (10 or 20 mg once daily)
Number of subjects: 28
Study 8357774 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 3900590 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil 80 mg every 8 hours for 5 days
Number of subjects: 141
Study 3900590 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 141
Study 29193822 — intervention group
Group type: EXPERIMENTAL
Intervention: Nidek AR‐360A autorefractometer
Number of subjects: 1238
Study 26546376 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm intraoperative imaging during fracture reduction
Number of subjects: 50
Study 26546376 — intervention group
Group type: COMPARATOR
Intervention: Post-surgery imaging for fracture reduction control
Number of subjects: 50
Study 24579804 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorsal onlay buccal mucosa graft (BMG) urethroplasty
Number of subjects: 37
Study 24579804 — intervention group
Group type: COMPARATOR
Intervention: Dorsal onlay penile skin flap (PSF) urethroplasty
Number of subjects: 37
Study 22656391 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol-free baby wipe
Number of subjects: 280
Study 22656391 — intervention group
Group type: COMPARATOR
Intervention: Cotton wool and water (usual care)
Number of subjects: 280
Study 19558428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole cream 0.5%
Number of subjects: 162
Study 19558428 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole cream 1%
Number of subjects: 162
Study 19558428 — intervention group
Group type: COMPARATOR
Intervention: Flutrimazole cream 1%
Number of subjects: 162
Study 17957184 — intervention group
Group type: EXPERIMENTAL
Intervention: Pitavastatin 4 mg
Number of subjects: 19
Study 17957184 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg
Number of subjects: 19
Study 17545266 — intervention group
Group type: EXPERIMENTAL
Intervention: Amalgam restorations
Number of subjects: 472
Study 17545266 — intervention group
Group type: COMPARATOR
Intervention: Composite restorations
Number of subjects: 472
Study 14722144 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication treatment (2-week course of omeprazole 20 mg, amoxicillin and clavulanate potassium 750 mg, and metronidazole 400 mg, all twice daily, n = 817)
Number of subjects: 1630
Study 14722144 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 813)
Number of subjects: 1630
Study 14722144 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori eradication treatment (n = 817)
Number of subjects: 1630
Study 10714087 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastrectomized patients
Number of subjects: 46
Study 10714087 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 46
Study 9181649 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef (200 mg twice daily for 10 days)
Number of subjects: 331
Study 9181649 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin (800/1000 mg twice daily for 10 days)
Number of subjects: 331
Study 9181649 — intervention group
Group type: EXPERIMENTAL
Intervention: Loracarbef
Number of subjects: 331
Study 9181649 — intervention group
Group type: COMPARATOR
Intervention: Phenoxymethylpenicillin
Number of subjects: 331
Study 1557934 — intervention group
Group type: EXPERIMENTAL
Intervention: SPf66 vaccine
Number of subjects: 399
Study 1557934 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 399
Study 4077772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-nitroimidazole compounds (including satranidazole, ronidazole, S75 0400 A)
Number of subjects: 0
Study 4077772 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 0
Study 4077772 — intervention group
Group type: EXPERIMENTAL
Intervention: Other antiprotozoal drugs (berberine sulphate, paromomycin sulphate, erythromycin estolate, sulphasalazine)
Number of subjects: 0
Study 31023329 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention (12-week program including education, social support, group discussion, follow-up calls, printed information)
Number of subjects: 40
Study 31023329 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity promoting intervention
Number of subjects: 40
Study 28824193 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg diclofenac suppository plus 5 mg isosorbide dinitrate sublingual tablet
Number of subjects: 900
Study 28824193 — intervention group
Group type: COMPARATOR
Intervention: 50 mg diclofenac suppository alone
Number of subjects: 900
Study 25770814 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant plus ondansetron on day 1, followed by aprepitant on days 2 and 3 (125 mg for ages 12-17 years; 3.0 mg/kg up to 125 mg for ages 6 months to <12 years; 80 mg for ages 12-17 years; 2.0 mg/kg up to 80 mg for ages 6 months to <12 years)
Number of subjects: 307
Study 25770814 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus ondansetron on day 1, followed by placebo on days 2 and 3
Number of subjects: 307
Study 23584582 — intervention group
Group type: EXPERIMENTAL
Intervention: PCV13
Number of subjects: 1709
Study 23584582 — intervention group
Group type: COMPARATOR
Intervention: PCV7
Number of subjects: 1709
Study 21591943 — intervention group
Group type: EXPERIMENTAL
Intervention: Alemtuzumab (30 mg, one dose)
Number of subjects: 474
Study 21591943 — intervention group
Group type: COMPARATOR
Intervention: Rabbit antithymocyte globulin (6 mg/kg over 4 days)
Number of subjects: 474
Study 21591943 — intervention group
Group type: COMPARATOR
Intervention: Basiliximab (40 mg over 4 days)
Number of subjects: 474
Study 19701033 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% lidocaine hydrochloride jelly
Number of subjects: 137
Study 19701033 — intervention group
Group type: COMPARATOR
Intervention: Plain aqueous gel
Number of subjects: 137
Study 16758747 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon
Number of subjects: 0
Study 12635973 — intervention group
Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a nice figure
Number of subjects: 330
Study 12635973 — intervention group
Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a nasty figure
Number of subjects: 330
Study 12635973 — intervention group
Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a neutrally characterised figure
Number of subjects: 330
Study 12635973 — intervention group
Group type: EXPERIMENTAL
Intervention: Colouring in a drawing of a neutral figure
Number of subjects: 330
Study 10874260 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombolytic therapy for myocardial infarction
Number of subjects: 0
Study 9114992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 10 mg once daily
Number of subjects: 209
Study 9114992 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetirizine 5 mg once daily
Number of subjects: 209
Study 9114992 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 209
Study 8261302 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible cystoscopy
Number of subjects: 53
Study 8261302 — intervention group
Group type: COMPARATOR
Intervention: Rod-lens cystoscopy
Number of subjects: 53
Study 4029404 — intervention group
Group type: EXPERIMENTAL
Intervention: Iridium implantation
Number of subjects: 47
Study 4029404 — intervention group
Group type: COMPARATOR
Intervention: External boost
Number of subjects: 47
Study 4029404 — intervention group
Group type: EXPERIMENTAL
Intervention: Periareolar incision
Number of subjects: 47
Study 4029404 — intervention group
Group type: COMPARATOR
Intervention: Other incisions
Number of subjects: 47
Study 4029404 — intervention group
Group type: EXPERIMENTAL
Intervention: Small and medium breasts
Number of subjects: 47
Study 4029404 — intervention group
Group type: COMPARATOR
Intervention: Large breasts
Number of subjects: 47
Study 30329030 — intervention group
Group type: EXPERIMENTAL
Intervention: Measles vaccination in the presence of maternal measles antibodies
Number of subjects: 0
Study 29949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Cabergoline (3 mg/week)
Number of subjects: 44
Study 29949429 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene (60 mg twice daily)
Number of subjects: 44
Study 27114605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab monotherapy (400 mg/m2 loading dose and then 250 mg/m2 once per week)
Number of subjects: 51
Study 27114605 — intervention group
Group type: EXPERIMENTAL
Intervention: Cetuximab plus irinotecan (cetuximab 400 mg/m2 loading dose and then 250 mg/m2 once per week with irinotecan 180 mg/m2 once every 2 weeks)
Number of subjects: 51
Study 25345071 — intervention group
Group type: EXPERIMENTAL
Intervention: Unspecific resistance training with dumbbells (12 repetition maximum squats)
Number of subjects: 57